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Steroid-resistant nephrotic syndrome (SRNS) almost invariably progresses to end-stage
renal disease. Although more than 50 monogenic causes of SRNS have been described, a
large proportion of SRNS remains unexplained. Recently, it was discovered that mutations
of NUP93 and NUP205, encoding 2 proteins of the inner ring subunit of the nuclear pore
complex (NPC), cause SRNS. Here, we describe mutations in genes encoding 4
components of the outer rings of the NPC, namely NUP107, NUP85, NUP133, and
NUP160, in 13 families with SRNS. Using coimmunoprecipitation experiments, we showed
that certain pathogenic alleles weakened the interaction between neighboring NPC
subunits. We demonstrated that morpholino knockdown of nup107, nup85, or nup133 in
Xenopus disrupted glomerulogenesis. Re-expression of WT mRNA, but not of mRNA
reflecting mutations from SRNS patients, mitigated this phenotype. We furthermore found
that CRISPR/Cas9 knockout of NUP107, NUP85, or NUP133 in podocytes activated
Cdc42, an important effector of SRNS pathogenesis. CRISPR/Cas9 knockout of nup107 or
nup85 in zebrafish caused developmental anomalies and early lethality. In contrast, an in-
frame mutation of nup107 did not affect survival, thus mimicking the allelic effects seen in
humans. In conclusion, we discovered here that mutations in 4 genes encoding components
of the outer ring subunits of the NPC cause SRNS and thereby provide further evidence that
specific hypomorphic mutations in these essential genes cause a distinct, […]
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Introduction
Steroid-resistant nephrotic syndrome (SRNS), a disease of the 
renal glomerular filter, is characterized by proteinuria, edema, 
and hypoalbuminemia. In contrast to other forms of nephrotic 
syndrome, SRNS does not respond to drug treatment and 
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NUP85, NUP133, and NUP160, in 29 individuals of 13 families 
with SRNS. Furthermore, we detected a homozygous mutation in 
NUP37 in a family with primary microcephaly, a phenotype that 
was also present in some families with NUP107 mutations. We 
use different in vivo and in vitro models to elucidate parts of the 
related pathogenesis.
Results
Hypomorphic mutations in 4 different genes encoding components 
of the outer ring subunits of the NPC cause nephrotic syndrome. To 
identify additional genes that cause SRNS if mutated, we per-
formed whole exome sequencing (25) in 160 families with SRNS. 
After excluding mutations in known SRNS genes, we used homo-
zygosity mapping (26) in consanguineous families to identify 
potentially novel candidate loci for SRNS. This approach yielded 
a homozygous missense mutation (c.303G>A, p.Met101Ile) in 
the gene NUP107 (NM_020401.3) (Table 1 and Figure 1, B–D) in 
consanguineous family A4649 with 3 affected siblings with SRNS 
and microcephaly. In 4 additional consanguineous families with 
a similar phenotype (B1426, A802, FA, PN-1), the NUP107 locus 
was positioned within a homozygous peak region, and we identi-
fied the same mutation in NUP107 (Figure 1, B–D, Supplemental 
Table 1, Supplemental Figure 1A, and Supplemental Figures 2 and 
3; supplemental material available online with this article; https://
doi.org/10.1172/JCI98688DS1). The p.Met101Ile mutation rep-
resents a South Asian founder allele that was reported previ-
ously in patients with the combined phenotype of SRNS and pri-
mary microcephaly (23, 27). Prior studies demonstrated that the 
p.Met101Ile mutation of NUP107 results in aberrant splicing and 
causes a reduction in the NUP107 protein level (23). NUP107 is an 
essential protein for NPC assembly (28, 29). In consanguineous 
family F797 with nonsyndromic SRNS, we found a homozygous 
missense mutation (c.2922T>G, p.Ser974Arg) in the gene NUP133 
(NM_018230.2), which was located within a homozygous peak 
region on chromosome 1 (Figure 1, H–J).
Because NUP133 and NUP107 encode 2 interacting compo-
nents of the outer ring subunits of the NPC, we hypothesized 
that alterations in other nuclear pore proteins may also cause 
monogenic SRNS. We therefore performed targeted sequencing 
of all exons of 19 genes that encode other NUPs in a worldwide 
cohort of 2,164 families with SRNS using a multiplex PCR–based 
high-throughput sequencing strategy (7, 30, 31) or using whole 
exome sequencing. As a result, we detected a homozygous mis-
sense mutation of NUP107 (c.2666A>G, p.Tyr889Cys) in family 
A3825 and 2 compound heterozygous alleles (c.1021dup, 
p.Glu341Glyfs*3, and c.2129_2131delAAG, p.Glu710del) of 
NUP107 in family A1830. None of these alleles were reported 
previously (Table 1 and Figure 1, A–D). All 5 families who carried 
the p.Met101Ile allele and family A1830 displayed the combined 
phenotype of SRNS with microcephaly and intellectual disabil-
ity. In contrast, family A3825 and 9 previously reported families 
with NUP107 alleles other than p.Met101Ile did not have a neu-
rodevelopmental phenotype (22, 24). We speculate that this 
allelism may be explained by the fact that only the homozygous 
p.Met101Ile allele resulted in a protein-truncating mutation (23), 
while all other families carried at least 1 recessive missense allele. 
This observation suggests that, as seen in other monogenic dis-
inevitably progresses to end-stage renal disease (ESRD), thus 
requiring dialysis or renal transplantation for survival (1). It 
constitutes the second most frequent cause of ESRD in the first 3 
decades of life (2). In SRNS, renal histology reveals focal segmental 
glomerulosclerosis or diffuse mesangial sclerosis, which indicate 
irreversible damage to the glomerulus. Mutations in over 50 genes 
have been discovered to cause monogenic SRNS (3, 4). These 
genetic findings have revealed podocytes, specialized epithelial 
cells of the glomerular filter, as the critical site of injury in SRNS 
(5, 6). Furthermore, identification of disease genes has implicated 
multiple signaling pathways in the molecular pathogenesis of 
SRNS (3). Our group and others have recently demonstrated 
that in about 30% of patients with SRNS a causative single-gene 
mutation can be identified (7–9).
The nuclear pore complex (NPC) is a large (100 MDa) macro-
molecular assembly that spans the nuclear envelope and forms a 
selective barrier between the cytoplasm and the nucleoplasm (10). 
The central channel of the NPC is filled with intrinsically disor-
dered proteins, which are rich in phenylalanine-glycine (FG) amino 
acid residues. These FG-rich nucleoporins (NUPs) establish a 
size-selective diffusion barrier to macromolecules greater than 
approximately 40 kDa while providing binding sites for nuclear 
transport receptors (karyopherins, importins, and exportins) that 
ferry signal-bearing cargo across the NPC (10). The central chan-
nel is supported by a structural scaffold built from the inner and 
outer ring complexes, which are formed by repeating modular 
units of the NUP93 subcomplex and the NUP107-160 complex, 
or “Y complex,” respectively (11, 12). The Y complex is the major 
subunit of the outer rings of the NPC. The atomic structures of the 
major domains of all 7 members of the Y complex (either alone or 
in complex), including NUPs 43, 85, 96, 107, 133, and 160, have 
been solved and modeled into electron cryomicroscopic maps of 
the human and Xenopus NPC (10).
Interestingly, while NUPs are best understood in their roles 
at the NPC, they also participate in additional functions in 
other subcellular locations (13–15). Studies in vertebrate model 
organisms additionally suggest that NUPs may have important 
regulatory functions during development and for tissue-specific 
progenitor cell maturation (16, 17). Genetic depletion of NUP 
transcripts caused severe developmental defects in zebra-
fish (18), mice (16), and frogs (15). Interestingly, some NUP- 
encoding genes show differential expression in different tissues 
and in different developmental stages (15, 19). NUPs studied 
in this article (i.e., nup107, nup85, nup133, and nup160) were 
shown to be expressed in both the rostral portion of the embryo 
(relevant to CNS development) and the intermediate mesoderm 
(important for pronephric development) (20).
Recently, we identified mutations in NUP93 and NUP205, 
encoding 2 components of the inner ring subunit of the NPC, in 
patients with nonsyndromic SRNS (21). Intriguingly, patients with 
mutations in NUP107, encoding a component of the Y complex, 
also developed SRNS (22–24). These observations suggest that 
a specific pathogenic link between SRNS development and 
alterations in different NUPs exists.
Performing whole exome sequencing and targeted exon 
sequencing, we here identified mutations in 4 genes encoding 
components of the outer ring subunits of the NPC, namely NUP107, 
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nese family, we discovered 2 compound heterozygous mutations 
(c.2407G>A, p.Glu803Lys, and c.2728C>T, p.Arg910*) in the 
gene NUP160 (NM_015231.1; Table 1 and Supplemental Figure 
4). NUP160 encodes a direct interaction partner of NUP85 within 
the Y complex (Figure 2A). The older sibling presented at age 16 
years with nephrotic syndrome that was resistant to therapy with 
steroids or other immunosuppressive drugs. His biopsy showed 
focal segmental glomerulosclerosis (FSGS), and his renal function 
was impaired (chronic kidney disease stage 3). The younger sister 
had proteinuria that first presented at age 7 years. Neither of the 
siblings displayed extrarenal symptoms (Table 1).
Twenty-five individuals of 13 families with recessive 
mutations of NUP107, NUP85, NUP133, or NUP160 had SRNS or 
proteinuria that manifested in childhood or adolescence (Table 1 
and Supplemental Table 1). In 13 of these 25 patients, the disease 
progressed to ESRD before age 25 years. A kidney biopsy was 
performed in 15 patients. In all cases, light microscopy showed 
sclerosis of renal glomeruli, manifesting as FSGS or diffuse 
mesangial sclerosis (Table 1, Supplemental Table 1, Figure 1, and 
Supplemental Figure 5). Electron microscopy furthermore revealed 
partial podocyte foot process effacement, one of the hallmark 
symptoms of nephrotic syndrome (Figure 1 and Supplemental 
Figure 5). We termed these previously unrecognized monogenic 
causes of SRNS as NPHS17 (NUP85), NPHS18 (NUP133), and 
NPHS19 (NUP160).
In a consanguineous Pakistani family with 3 affected chil-
dren with congenital microcephaly, we discovered a homozygous 
nonsense mutation (c.916C>T, p.Arg306*) in the gene NUP37 
(NM_024057.3) (Table 1 and Supplemental Figure 6). NUP37 
encodes an essential component of the Y complex of the NPC. 
Segregation analysis was performed when possible, and was com-
patible with a recessive mode of inheritance (Supplemental Fig-
ure 6). All 3 patients showed congenital microcephaly (–5 to –8 
standard deviations [SD]), mild intellectual disability, cerebellar 
vermis hypoplasia, and clinodactyly of the fifth finger (Table 1). 
Proteinuria was not present in these patients, and renal ultrasound 
examination did not reveal any abnormalities (Table 1).
Mutations from SRNS patients impair intermolecular interactions 
between NPC components. NUP107, NUP85, NUP133, and NUP160 
are components of the Y complex, whose molecular structure has 
recently been modeled into the outer ring scaffold of the NPC (11) 
(Figure 2A). To investigate the pathogenicity of alleles that we 
discovered in SRNS patients, we gleaned from available structural 
data (Protein Data Bank, pdb: 5A9Q) (11) that 1 mutation of 
NUP133, p.Ser974Arg, and 1 mutation of NUP107, p.Tyr889Cys, 
were located in the interacting α-helix between the 2 proteins 
(Figure 2A). NUP85 mutations were positioned within a region for 
which no molecular structure of the human Y complex is available 
yet (Figure 2A).
We used cDNA constructs reflecting the mutations identified 
in patients with SRNS (Table 1) and performed half-endogenous 
coimmunoprecipitation (coIP) experiments in HEK293T cells. 
These experiments demonstrated that, as predicted based on 
the structural data, the alleles p.Tyr889Cys of NUP107 and 
p.Ser974Arg of NUP133 weakened the interaction between 
NUP107 and its direct binding partner NUP133 (Figure 2, B 
and C). Other missense alleles of NUP107 or NUP133 did not 
eases (32), severe mutations in NUP genes cause syndromic 
phenotypes, while milder mutations give rise to distinct organ-
specific phenotypes. Besides microcephaly, 2 families (B1426 
and A3825) showed additional skeletal/facial phenotypes (in 
particular arachnodactyly, high arched palate, and cleft palate/
lip), and 1 family (A802) had congenital heart disease (Table 1 
and Supplemental Table 1). The targeted screening additionally 
identified 2 segregating, compound heterozygous mutations of 
NUP133 (c.691C>G, p.Arg231Gly, and c.3164T>C, p.Leu1055Ser, 
NM_018230.2) in family A2174 with nonsyndromic SRNS (Figure 
1, I and K; Supplemental Figure 1C; and Table 1).
High-throughput exon sequencing furthermore yielded 3 
mutant alleles of NUP85 (NM_024844.4), encoding a different com-
ponent of the outer rings of the NPC, in 4 individuals of 3 unrelated 
families with SRNS (families A5195, A3259, and NCR3227/3310) 
(Figure 1, E–G; Supplemental Figure 1B; and Table 1). Two mutations 
were homozygous missense mutations (c.1430C>T, p.Ala477Val, 
and c.1933C>T, p.Arg645Trp). One family (NCR3227/3310) carried 
2 compound heterozygous alleles (c.405+1G>A and c.1741G>C, 
p.Ala581Pro), which segregated from the maternal and the paternal 
side, respectively (Table 1). All families with NUP85 mutations had 
SRNS and microscopic hematuria, a finding that can be associated 
with SRNS. Family NCR3227/3310 additionally displayed intellec-
tual disability, but showed no structural brain defects. Interestingly, 
in several families with NUP107 or NUP85 mutations, short stat-
ure was noted as a clinical feature, and family NCR3227/3310 had 
partial growth hormone deficiency.
Using the list of 19 candidate genes for targeted evaluation 
of whole exome sequencing data in a non-consanguineous Chi-
Figure 1. Homozygosity mapping and whole exome sequencing identify 
recessive mutations of NUP107, NUP85, and NUP133 in 12 families with 
steroid-resistant nephrotic syndrome. (A) Renal histology of individual 
A3825-21 (NUP107 mutation) shows diffuse mesangial sclerosis on light 
microscopy. (B, F, and I) Exon structure of human cDNAs. Positions of start 
codons and of stop codon are indicated. For protein domain structures, 
α-helices are depicted as red zigzag lines and β-turns as purple arrows. 
Arrows indicate positions of pathogenic mutations detected in families 
with SRNS. H, homozygous; h, heterozygous. (B) Exon structure, protein 
domain structure, and human mutations of NUP107. (C) Homozygosity  
mapping identifies 3 recessive candidate loci (red circles) in patient 
A4649-21. Nonparametric lod (NPL) scores and SNP positions (Affymetrix 
250K StyI array) are plotted on human chromosomes concatenated from 
p-ter (left) to q-ter (right). Genetic distance is given in centimorgans (cM). 
Whole exome sequencing identifies a homozygous mutation of NUP107 
(p.Met101Ile) that is positioned within the maximum NPL peak on chromo-
some 12 (arrowhead). (D, G, and K) Evolutionary conservation of amino 
acid residues that are altered in patients with SRNS. (D) Altered amino 
acid residues of NUP107 (p.Met101Ile, p.Tyr889Cys). (E) Renal histology of 
A3259-21 (NUP85 mutation) showing podocyte foot process effacement on 
transmission electron microscopy (TEM) (arrowheads). (F) Exon structure, 
protein domain structure, and human mutations of NUP85. (G) Altered 
amino acid residues of NUP85 (p.Ala477Val, p.Ala581Pro, p.Arg645Trp). (H) 
Renal histology of individual F797-21 (NUP133 mutation) shows podocyte 
foot process effacement on TEM (arrowheads). (I) Exon structure, protein 
domain structure, and human mutations of NUP133. (J) Homozygosity 
mapping in individual F797-21 identifies regions of homozygosity as reces-
sive candidate loci. Within the maximum NPL peak on chromosome 1  
(arrowhead), we identified a homozygous mutation in NUP133 
(p.Ser974Arg). (K) Altered amino acid residues of NUP133 (p.Arg231Gly, 
p.Ser974Arg, p.Leu1055Ser).
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Figure 2. Mutations of NUP107, NUP85, and 
NUP133 weaken protein-protein interactions 
within the NPC. (A) The published structure 
of the Y complex of the NPC (11) was used to 
determine the localization of amino acid residues 
that we found altered in individuals with SRNS. 
Left: The 3D structure of the Y complex (pdb: 
5A9Q): NUP133 (dark blue), NUP107 (light green), 
NUP96 (light blue), SEC13 (orange), SEH1L (violet), 
NUP85 (light gray), NUP43 (dark green), NUP160 
(yellow), and NUP37 (red). Inset on right: The 3D 
structure of the interface region between NUP107 
and NUP133 (pdb: 3CQC). The C-terminal part of 
NUP85 could not be fully resolved experimentally; 
a gray area indicates its predicted position. Resi-
dues Ala477, Ala581, and Arg645 of NUP85 (gray) 
and Glu803 of NUP160 (yellow) are located within 
incompletely resolved areas, and their positions 
are estimated. Note that amino acid residues 
Tyr889 of NUP107 (light green) and Ser974 of 
NUP133 (dark blue) point toward the interaction 
interface. (B) N-terminally FLAG-tagged NUP107 
wild-type (WT) or mutant cDNA was overex-
pressed in HEK293T cells. Coimmunoprecipitation 
(coIP) demonstrates that the missense muta-
tion Tyr889Cys weakens the interaction with 
endogenous NUP133. (C) A coIP experiment using 
N-terminally FLAG-tagged WT or mutant NUP133 
cDNA demonstrates that the missense mutation 
Ser974Arg weakens the interaction with endog-
enous NUP107. As expected based on structural 
data, the 2 other missense mutations (Arg231Gly 
and Leu1055Ser) do not alter the NUP107-NUP133 
interaction. (D) N-terminally Myc-tagged WT 
or mutant NUP85 cDNA was overexpressed in 
HEK293T cells. CoIP using an antibody against 
endogenous NUP160 shows that the missense 
mutations Ala581Pro and Arg645Trp of NUP85 
weaken the interaction between the 2 proteins. 
FL, full-length; MOCK, empty vector. CoIP experi-
ments in B–D were confirmed in 3 independent 
experiments.
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interfere with the interaction between the 2 proteins. We fur-
thermore show that the missense mutations p.Ala581Pro and 
p.Arg645Trp of NUP85 weakened the interaction with its binding 
partner NUP160 (Figure 2D). The obligatory splice site mutation 
c.405+1G>A of NUP85 is predicted to cause skipping of exon 5, 
thus resulting in a frameshift with premature truncating of the 
encoded protein. We modeled this mutation in a cDNA construct 
and found that it completely abrogated the interaction between 
NUP85 and NUP160 (Figure 2D). Confirmatory experiments for 
all coIPs using differently tagged fusion proteins are shown in 
Supplemental Figure 7. Next, we aimed to investigate the impact 
of an isolated depletion of SRNS-relevant NUPs on other compo-
nents of the NPC. To address this question, we generated immor-
talized human podocyte cell lines with doxycycline-inducible 
CRISPR/Cas9 mediated knockout of NUP107, NUP85, or NUP133 
(Supplemental Figures 8–10 demonstrate successful depletion 
of targeted proteins). We used an inducible system because 
sustained knockout of any of the 3 investigated NUP genes had 
strong effects on cell viability, which we feared would mask any 
specific effects resulting from the knockout. Using the induc-
ible CRISPR/Cas9 system, we could instead initiate depletion of 
the specific gene of interest shortly before the experiment and 
thereby study its direct effect. In this setting, we did not observe 
significant cell death. Interestingly, we found that short-term 
depletion of NUP85 or NUP133 had very little effect on the protein 
levels of other components of the NPC (Supplemental Figure 11).
Morpholino knockdown of Xenopus nup107, nup85, or nup133 
causes defects in glomerulogenesis. At the 2-cell stage, Xenopus 
embryos were injected with a morpholino oligonucleotide targeting 
nup85, nup107, or nup133. In Xenopus, cell divisions are holoblastic 
(complete); therefore, we can do lateralized injections of 1 cell at 
the 2-cell stage such that only half of the animal is affected during 
development. In this setting, the uninjected side can act as an inter-
nal control. In contrast, the initial cleavages of zebrafish embryos 
are mesoblastic (incomplete); as a consequence, injected mRNAs 
cannot be localized to just 1 cell. For this reason, Xenopus is an ideal 
system in which to test rescue especially of lateralized structures 
such as the kidney (Figure 3A). At stage 35–37, we detected the 
pronephros using atp1a1 as a marker in whole-mount in situ 
hybridization experiments. At this stage, the proximal portion of the 
pronephros develops a convoluted shape that subsequently 
straightens out as it extends to the posterior portion of the embryo.
We categorized defects in pronephros morphology based on 
their severity (Figure 3B). Compared with controls (Figure 3, C 
and D), morpholino knockdown resulted in abnormal pronephros 
morphology in 65% of nup85 morphants (Figure 3, E vs. F, and K), 
38% of nup107 morphants (Figure 3, G vs. H, and K), and 86% of 
nup133 morphants (Figure 3, I vs. J, and K). Morpholino knockdown 
of pax8, which encodes an essential transcription factor in renal 
development, was used as a positive control to validate this 
approach (Supplemental Figure 12A). We used the gene NUP155 
as a negative control, because the phenotype caused by NUP155 
mutations, monogenic atrial fibrillation (33), does not involve 
the kidney. As expected, knockdown of nup155 did not result in a 
renal phenotype in the Xenopus model (Supplemental Figure 12B). 
These findings suggest that the nucleoporins Nup85, Nup107, and 
Nup133 are required for renal development in Xenopus.
In order to test the specificity of the knockdown experiment 
and to assess the pathogenicity of human mutations, we used 
rescue experiments (Supplemental Figure 13). We first injected 
nup85, nup107, or nup133 morpholinos at the 1-cell stage to deplete 
these proteins throughout the embryo. At the 2-cell stage, we then 
injected 1 cell of these morphants with WT or mutant human 
mRNA of NUP85, NUP107, or NUP133, respectively (Supplemental 
Figure 13A). While WT mRNA rescued the abnormal kidney 
morphology seen in morphant kidneys, mutant mRNA reflecting 
the human SRNS mutations resulted in an impaired restoration 
of renal morphology (Supplemental Figure 13, B–D). Only the 
p.Ala477Val variant of NUP85 did not show a significantly reduced 
rescue efficiency. Based on this result, we would predict that this 
allele may have some residual function, and that it may represent 
a relatively mild allele as compared with the others. Interestingly, 
the phenotype in those patients was not notably different.
CRISPR/Cas9 knockout of NUP107, NUP85, or NUP133 increases 
the level of active Cdc42. Dysregulation of the Rho-like small GTPases 
RhoA, Rac1, and Cdc42, resulting in impaired actin dynamics, plays 
an important role in the pathogenesis of monogenic SRNS (34–39). 
Interestingly, we observed that CRISPR/Cas9–mediated knockout 
of NUP107, NUP85, or NUP133 increased the formation of filopodia 
in immortalized human podocytes (Figure 4, A and B), suggesting 
that loss of function of these genes alters the podocyte’s cytoskeleton. 
Because Cdc42 is known to induce filopodia formation, if active 
(40), we performed the colorimetric Cdc42 G-LISA Activation Assay 
to determine the cellular level of active Cdc42. We found that in 
comparison with control cells (Cas9 expression but no guide RNA 
[gRNA]), CRISPR/Cas9 knockout of any of the 3 genes significantly 
increased Cdc42 activity (Figure 4C). However, when using the 
IncuCyte system to assess the migration rate of podocytes, we did 
not find a significant difference between control and knockout cells 
(Supplemental Figure 14).
Truncating mutations of nup107 or nup85 in zebrafish induce early 
lethality, while an in-frame mutation of nup107 does not affect survival. 
We designed gRNAs targeting exon 2 of nup107, the zebrafish 
ortholog (NM_001030167.1). Using CRISPR/Cas9 technology, we 
then generated 2 different stable zebrafish lines, one with a protein-
truncating “null” allele (c.50_56del7, p.Thr81Argfs*74) and one 
with an in-frame mutation, most likely acting as a hypomorphic 
allele (c.137_139del3, p.Ala46delAla). After het × het in-crossing, 
we monitored survival twice daily and generated Kaplan-Meier 
survival curves. Zebrafish with a homozygous truncating mutation 
of nup107 showed early lethality at 5 days postfertilization 
(dpf) (Figure 5A) and demonstrated severe developmental 
malformations, including small eyes, ventral body axis curvature, 
periorbital edema, and total body edema (Figure 5, C–G, and Table 
2). These phenotypes developed at 4 dpf before death on 5 dpf. 
Zebrafish were born at Mendelian ratios. None of the 29 larvae 
homozygous for the null allele p.Thr81Argfs*74 were phenotypically 
normal. Conversely, none of the 42 heterozygous larvae and none 
of the 34 WT larvae developed any overt phenotype (Table 2). In 
contrast to the truncating allele, the hypomorphic mutation of 
nup107 did not affect survival of zebrafish larvae (Figure 5B) and 
did not result in any overt phenotype (data not shown).
We then used CRISPR/Cas9 technology and a gRNA tar-
geting exon 4 of nup85 (NM_001003625.1) to generate a 
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Figure 3. Morpholino knockdown of nup85, nup107, or nup133 in Xenopus embryos causes 
defects in glomerulogenesis. Xenopus embryos were injected with morpholino oligonucle-
otides (MOs) targeting nup85, nup107, or nup133 at the 2-cell stage. Abnormalities in pronephric 
development, specifically improper formation of the convoluted pronephric duct, were scored at 
stages 35–37. The pronephros was detected using whole-mount in situ hybridization and atp1a1 
as a marker. (A) Schematic of the experimental setup, in which injection of MO into 1 cell of a 
2-cell embryo allows for 1 side of the embryo to develop normally, while the other half serves as 
an internal control for developmental phenotypes. (B) Based on the severity of the phenotype, 
morphants were sorted into 4 groups: normal, mild phenotype (delayed or decreased convolu-
tion of the pronephric duct, top panel), moderate phenotype (loss of the characteristic pronephric 
architecture, middle panel), and severe phenotype (pronephros entirely absent, bottom panel). 
Shown here are examples for each category. (C–J) Left panels display the uninjected control 
side. Right panels display the injected side. (C and D) Control embryo (injected with nontarget-
ing MO) displaying appropriate pronephric morphology for this stage (see B). (C) Uninjected. (D) 
Injected. (E and F) MO knockdown of nup85 results in abnormalities of pronephric development. 
(E) Uninjected. (F) Injected. (G and H) MO knockdown of nup107 causes developmental defects of 
the pronephros. Note the developmental delay and simplification of the convoluted pronephric 
duct. (G) Uninjected. (H) Injected. (I and J) Morpholino knockdown of nup133 causes pronephric 
developmental abnormalities. (I) Uninjected. (J) Injected. (K) Phenotypes in nup85, nup107, nup133, 
or nup155 morphants were categorized into the 4 groups. Note that as compared with uninjected 
controls (UC, n = 32), nup85 (65% abnormal, n = 34) and nup133 (86% abnormal, n = 28) morphants 
more frequently display severe phenotypes, while nup107 (38% abnormal, n = 34) morphants tend 
to show milder phenotypes. All experiments were performed at least twice.
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To test for renal anomalies and for a kidney-specific pheno-
type, we used transmission electron microscopy (TEM) to inves-
tigate the ultrastructure of the renal glomerulus and used H&E 
staining to study renal histology. For the 2 null alleles of nup107 
and nup85, we investigated 2 homozygous versus 2 heterozygous 
fish by TEM and 8 homozygous versus 8 heterozygous fish by 
renal histology for each gene. We detected significant tissue decay 
within the glomerular region, but also globally throughout the 
zebra fish line carrying the truncating mutation p.Arg107Cysfs*15 
of nup85, the zebrafish ortholog of human NUP85. As observed 
with nup107 knockout, homozygous nup85-knockout fish 
showed early lethality and died at day 8 dpf (Supplemental 
Figure 15A). The phenotypic features of nup85-knockout fish 
resembled those of nup107-knockout fish, including small eyes, 
body axis curvature, and edema (Supplemental Figure 15, B–E, 
and Supplemental Table 2).
Figure 4. CRISPR/Cas9–mediated knockout of NUP107, NUP85, or NUP133 induces filopodia formation and increases active Cdc42 in human podocytes. 
Immortalized human podocytes underwent lentiviral transduction with a plasmid expressing a Cas9-GFP fusion construct under the control of a doxycycline-
inducible promoter and a single gRNA. For each gene, 2 different cell lines were generated expressing gRNAs against NUP107 (targeting exon 4 or 11), 
NUP85 (targeting exon 1 or 15), or NUP133 (targeting exon 1 or 5), respectively. Experiments were performed 72 hours after induction of Cas9 expression with 
doxycycline (1 μg/ml). (A) We stained immortalized human podocytes expressing empty vector (MOCK) or individual gRNAs targeting NUP107, NUP85, or 
NUP133 with phalloidin to detect F-actin fibers. Podocytes that had either 3 actin-based protrusions or 1 filamentous protrusion of more than one-quarter of 
the cell body were quantified as “filopodia positive.” Representative images showing “filopodia-negative” control cells and NUP107-, NUP85-, or NUP133-
knockout podocytes that exhibited filopodia (arrowheads). Scale bars: 25 μm. The result was confirmed in 3 independent experiments. (B) Quantification 
of approximately 50 cells for each condition resulted in 22% of MOCK-expressing cells with filopodia (11/50), in contrast to 58% (29/50) for NUP107 gRNA 
exon 4 (ex4) and 46% (23/50) for NUP107 gRNA ex11; 50% (25/50) for NUP85 gRNA ex1 and 54% (30/56) for NUP85 gRNA ex15; and 44% (22/50) for NUP133 
gRNA ex1 and 38% (19/50) for NUP133 gRNA ex5. Note that knockout podocytes show increased filopodia formation. (C) Using the colorimetric G-Lisa 
Cdc42 Activation Assay Biochem Kit (Cytoskeleton), we demonstrate an increase in the active state of Cdc42 following CRISPR/Cas9–mediated knockout of 
NUP107, NUP85, or NUP133 in human podocytes. Data points represent 3 independent experiments (highlighted in different colors) and are displayed with 
mean and SD. P values calculated by 1-way ANOVA are indicated in the figure as *P < 0.05; **P < 0.01.
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(LCL) from a patient with the p.Met101Ile mutation of NUP107 
(Supplemental Figure 16, A–C). These findings suggest that, as 
previously described (28, 29), proteins of the Y complex depend 
on each other for protein stability. Interestingly, in both cell lines 
residual amounts of the mutant protein were present.
When investigating the consequences of reduced NUP37 
amounts for NPC density, we found a reduced intensity of the 
mAb414 antibody signal, suggesting a lower number of nuclear 
pores in mutant fibroblasts as compared with control cells (Figure 6, 
E and F). Using antibodies detecting heterochromatin (anti-HP1β; 
Figure 6G) and nucleoli (anti-fibrillarin; Figure 6, H and I), we 
demonstrated an alteration of chromatin organization and nucleo-
lar morphology in NUP37 mutant fibroblasts. TEM confirmed this 
observation (Figure 6, J–M, arrowheads). Additionally, we found 
larva. We are therefore hesitant to interpret these findings as a 
specific podocyte phenotype, but rather assume that the loss of an 
essential protein induces injury in all cell types.
Primary patient cell lines carrying protein-truncating mutations 
of NUP37 and NUP107 display changes in NPC composition and 
nuclear morphology. We obtained primary cell lines from 2 patients 
with microcephaly and with mutations of NUP37 and NUP107, 
respectively. In dermal fibroblasts from a patient carrying the 
p.Arg306* allele of NUP37, we demonstrated that at the mRNA 
(Supplemental Figure 6E) and protein level (Figure 6, A and D) 
NUP37 was reduced in comparison with control cells. Reduced 
NUP37 protein levels resulted in codepletion of other components 
of the Y complex, such as NUP107 and NUP160 (Figure 6, 
A–D). A similar effect was observed in a lymphoblastoid cell line 
Figure 5. A truncating mutation but not a hypo-
morphic mutation of nup107 causes early lethality 
and developmental defects in zebrafish. Zebrafish 
lines with mutations of nup107 were generated using 
CRISPR/Cas9 technology. Lethality following het × 
het in-crossing was monitored twice daily over the 
indicated periods. Genotyping was performed in all 
fish and was compatible with Mendelian ratios. (A) 
Kaplan-Meier survival curves of 86 larvae demonstrate 
that homozygous (hom) larvae carrying the frameshift 
mutation p.Thr81Argfs*74 of nup107 died before 5 dpf, 
contrary to heterozygous (het) and wild-type (WT) 
controls (n = 26 hom, 39 het, 21 WT). (B) Kaplan-Meier 
survival curves of a zebrafish line carrying a hypo-
morphic mutation of nup107 (p.Ala46delAla). Note 
that, contrary to the truncating allele, this in-frame 
deletion of nup107 does not impair survival of homo-
zygous larvae compared with WT fish or heterozy-
gous clutch mates (n = 14 hom, 27 het, 15 WT). (C–G) 
Phenotypes of homozygous nup107-knockout larvae 
(p.Thr81Argfs*74) on day 4 dpf. Specifically, the pheno-
type included small eyes, ventral body axis curvature, 
and peripheral as well as periorbital edema. (C and D) 
Yellow circumferences drawn around the pigmented 
area of the eyes of knockout fish (C) versus heterozy-
gous clutch mates (D) assess eye size using ImageJ. (E) 
Quantification of eye size measurements (see C and D) 
demonstrates significantly smaller eyes in homozy-
gous fish compared with heterozygous or WT clutch 
mates. One-way ANOVA with a standard confidence 
interval of 95% results in F(2, 84) = 84.72; P < 0.0001. 
Two-tailed P values (Šidák’s multiple-comparisons 
test) are shown in the figure (****P < 0.001). (F) Rep-
resentative image showing ventral body axis curvature 
in a homozygous knockout fish. (G) Representative 
image displaying body and periorbital edema in a 
homozygous knockout fish. For quantification of F and 
G, see Table 2. Scale bars in C, D, F, and G: 500 μm.
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The Rho-like small GTPases RhoA, Rac1, and Cdc42 are regu-
lators of the actin cytoskeleton (43). Podocytes depend on a highly 
dynamic and tightly regulated actin cytoskeleton to generate and 
maintain their actin-based foot processes and the slit membrane of 
the renal glomerular filter (39). Dysregulation of these Rho-like small 
GTPases has been observed in several monogenic forms (34–37, 41) 
and mouse models of SRNS (38, 44). We therefore propose that the 
observed increase in the level of active Cdc42 upon knockout of 
NUP85, NUP107, or NUP133 may contribute to the pathogenesis of 
SRNS in patients with mutations in these genes. Mechanistically, fur-
ther studies will be needed to elucidate the molecular link between 
NPC disruption and dysregulation of Cdc42 activity. However, based 
on currently available data, it seems likely that alterations in NUPs 
are linked to the activity state of Cdc42 by an indirect effect. This 
functional link may be mediated, e.g., by nuclear import of specific 
regulatory elements or by nuclear export of distinct RNA species.
Prominent phenotypic features of nup107- and nup85-knockout 
zebrafish larvae included edema, ventral body axis curvature, and 
diminished eye size. This phenotype recapitulated a previously 
published transcription activator–like effector nuclease–mediated 
(TALEN-mediated) nup107-knockout zebrafish line (18). Before 
death, knockout zebrafish showed profound decay in all tissues, 
including the glomerular area. However, because of its global char-
acter, we are hesitant to interpret these findings as a tissue-specific 
phenotype. We assume that knockout larvae die prematurely as 
a result of the complete lack of Nup85 and Nup107, two essential 
proteins, before a specific renal phenotype may develop.
Summarizing all findings, we suggest the following explanation 
for the observed genotype-phenotype correlation in patients 
with NUP107 mutations: While missense mutations likely have 
little impact on protein stability and cellular protein level, the 
p.Met101Ile allele of NUP107 resulted in a reduced amount of 
NUP107 protein with consecutive changes in NPC composition 
and nuclear organization. In conclusion, we propose that 3 types 
of mutations in essential NUP-encoding genes exist: (a) complete-
loss-of-function mutations that cause embryonic lethality and 
are therefore not observed in human patients; (b) partial-loss-of- 
function mutations that reduce the amount of the encoded 
proteins and cause syndromic, developmental phenotypes, but are 
compatible with survival; and (c) strictly hypomorphic missense 
mutations that impair only specific aspects of the protein’s 
functionality without affecting its overall function and therefore 
result in a distinct, organ-restricted phenotype.
Mutations in the genes NUP93, NUP205, and NUP107, 
encoding proteins of the NPC, were recently described as causing 
SRNS (21–24). It was vexing that mutations in these essential 
genes of high evolutionary conservation and universal relevance 
gave rise to such a distinct phenotype. By identifying 3 additional 
genes that encode scaffold proteins of the NPC and cause SRNS, if 
mutated, we provide further evidence that distinct, hypomorphic 
mutations in this group of fundamental genes may specifically 
impact podocytes and may manifest in a cell type–specific manner.
Methods
Study participants. We collected blood samples and pedigree 
information after informed consent from individuals with SRNS or 
their guardians.
the perinuclear space to be widened and irregular (Figure 6, L 
and M, arrows), and we detected bulbous invasions of the nuclear 
envelope (Figure 6M, star) in NUP37 mutant fibroblasts. Nota-
bly, the cell proliferation rate of NUP37-mutant as compared with 
control fibroblasts was reduced (Supplemental Figure 6F). We 
admit that, as mutations in NUP genes predominantly manifest in 
postmitotic, epithelial tissues, proliferating fibroblasts have impor-
tant limitations as a model system.
Discussion
In summary, we here discovered recessive mutations in the genes 
NUP85, NUP133, and NUP160 as 3 monogenic causes of SRNS. 
Interestingly, all 3 genes and the gene NUP107, in which we found 
3 pathogenic alleles, encode proteins that are components of a 
distinct subunit of the nuclear pore complex (NPC), the so-called 
Y complex or outer ring subunit of the NPC. In coIP experiments, 
we demonstrated that 5 human mutations altered protein-protein 
interaction between direct binding partners in the NPC. Using 
morpholino knockdown in Xenopus larvae, we provided evidence 
that these NUPs play a distinct role in renal development. The 
renal phenotype of Xenopus morphants could be rescued by WT, 
but not mutant, mRNA, thus demonstrating pathogenicity for the 
alleles that we identified in patients with SRNS. In contrast to all 
other tested alleles, the p.Ala477Val allele of NUP85 rescued the 
phenotype, thereby suggesting that in this case the function of 
the encoded protein was at least partially preserved. This result 
may be explained by (a) the mild chemical difference between 
WT and altered amino acid (alanine vs. valine) and (b) the fact 
that this residue was not conserved between the human and the 
frog protein. As there was no difference in the severity of the 
phenotype in affected patients, we assume that the function of the 
human protein may still be significantly altered by this mutation. 
In cell culture studies, we observed that knockout of NUP107, 
NUP85, or NUP133 in immortalized human podocytes changed the 
activity state of the Rho-like small GTPase Cdc42, a pathway that 
is known to be relevant to monogenic forms of SRNS (34–37, 41). 
When generating stable, transgenic zebrafish lines using CRISPR/
Cas9 technology, we observed that null alleles of nup107 or nup85 
caused severe developmental malformations and early lethality. 
In contrast, an in-frame mutation of nup107 was compatible with 
survival and did not cause apparent developmental anomalies, thus 
reflecting the allelism seen in patients with NUP107 mutations.
Accumulating evidence suggests that apart from their universal 
function in nucleocytoplasmic transport, certain NUP proteins may 
have additional, individual functions in cell differentiation and dur-
ing development (16, 42). By performing morpholino knockdown 
experiments, we generated the first evidence to our knowledge that 
Nup107, Nup85, and Nup133 are required for renal development in 
Xenopus. The observation that knockdown of nup155 did not result 
in abnormal pronephros morphology suggests that this function 
is specific to certain NUPs. With one exception, mutant mRNAs, 
reflecting alleles that we found mutated in SRNS patients, were less 
efficient than WT mRNA in restoring the pronephros morphology 
in Xenopus morphants. Based on these observations, we hypothe-
size that SRNS development in patients with mutations of NUP107, 
NUP85, or NUP133 partially reflects an alteration of specific func-
tions of those NUPs during renal development.
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paired-end sequencing on an Illumina MiSeq instrument (Illumina) to 
sequence the coding regions of 19 genes that encode different NUPs in 
2,164 individuals with nephrotic syndrome. Bioinformatic analysis was 
conducted using CLC Genomics Workbench software (version 6.5.2; 
CLC bio). Identified mutations were confirmed by Sanger sequencing. 
Segregation analysis was performed whenever possible (Table 1).
In silico modeling of NUP85, NUP107, and NUP133 mutations. The 
model of the human Y complex (outer ring subunit of the NPC) was 
based on published data available from the Protein Data Bank (pdb). 
Figure 2A is based on pdb structures 5A9Q (11) and 3CQC (55). We 
used the open-source program Jmol (an open-source Java viewer for 
chemical structures in 3D; http://www.jmol.org/) to generate the 3D 
projections that are shown in Figure 2.
cDNA cloning and stable CRISPR/Cas9 cell lines. The follow-
ing human cDNA constructs were used for this study: NUP107 
(NM_020401.3), NUP85 (NM_024844.4), and NUP133 (NM_018230.2). 
The following expression vectors were used for cell culture experi-
ments: pRK5-N-Myc, pDEST69-N-Flag, and pCDNA6.2-N-GFP. The 
inducible CRISPR/Cas9 backbone (TLCV2) was a gift from Adam 
Karpf (Eppley Institute, University of Nebraska Medical Center, Oma-
ha, Nebraska, USA) (Addgene plasmid 87360). This backbone is based 
on LentiCRISPR-v2 and expresses Cas9-P2A-GFP under the control of 
a doxycycline-inducible promoter (tight TRE promoter). Additionally, 
a single gRNA and a puromycin-resistance cassette are expressed con-
stitutively. Stable cell lines were generated using lentiviral transduction 
and puromycin selection (4 μg/ml) for more than 7 days. Cas9 expres-
sion was induced 72 hours before all experiments using doxycycline (1 
μg/ml). Western blotting and immunofluorescence experiments con-
firmed a reduction in the expression level of targeted proteins (Supple-
mental Figures 8–10).
gRNA sequences are provided in Supplemental Table 3.
Antibodies are listed in Supplemental Table 4.
Cell lines. Immortalized human podocytes were a gift from Moin 
Saleem (University of Bristol, Bristol, United Kingdom) and have been 
extensively characterized in previous publications (56). HEK293T 
cells were purchased from the ATCC biological resource center and 
were used for virus production and coIP experiments. Cells were 
tested monthly for mycoplasma contamination. Primary cell lines, i.e., 
human dermal fibroblasts or lymphoblastoid cell lines (LCLs) from 
patients with a homozygous mutation of NUP107 (PN-1) or NUP37 
(PN-2), were generated as described previously (57, 58).
Coimmunoprecipitation. CoIP experiments were performed in 
HEK293T cells. Thirty-six hours after cDNA transfection, protein 
lysates were harvested, and 450–600 μg of protein was incubated for 
4 hours with (a) EZview Red Anti-c-Myc Affinity Gel (Sigma-Aldrich), 
(b) EZview Red ANTI-FLAG M2 Affinity Gel (Sigma-Aldrich), or (c) 
Chromotek-GFP-Trap Agarose Beads (Allele Biotechnology) depending 
on the expressed fusion protein and as indicated in the figures. Before 
elution, beads were washed 5 times with IP lysis buffer (Thermo Fisher 
Scientific). The result of each coIP study was confirmed in 3 independent 
experiments and was repeated using differently tagged fusion proteins.
Phenotyping in Xenopus embryos. Antisense morpholino oligonu-
cleotides (MOs) or mRNAs were injected either at the 1-cell stage or 
into 1 cell of the 2-cell embryo as previously described (59). Sequences 
of MOs are provided in Supplemental Table 3. We generated mRNA 
of WT and mutated human sequences using a T7 promoter template 
in the pcDNA6.2-N-GFP backbone. In vitro capped mRNA was gener-
Homozygosity mapping. Homozygosity mapping was performed 
using the GeneChip Human Mapping 250k StyI Array, Affymetrix, 
and the programs GENEHUNTER 2.1 (45, 46) and ALLEGRO (47) as 
described previously (48). Alternatively, homozygosity mapping was 
generated based on whole exome sequencing data using the Genome 
Analysis Tool Kit (49) and the program Homozygosity Mapper (50). For 
families PN-1 and PN-2, the Illumina HumanCoreExome 24 v1.1 array 
(Illumina) was used for genotyping. Further analysis was performed 
as described previously (51). See Supplemental Methods for a more 
detailed description.
Whole exome sequencing. Whole exome sequencing was performed 
on genomic DNA isolated from blood lymphocytes or saliva and 
subjected to exome capture using Agilent SureSelect human exome 
capture arrays (Agilent Technologies) followed by next-generation 
sequencing on a HiSeq Illumina sequencing platform. Sequence reads 
were mapped to the human reference genome (NCBI build 37/hg19) 
using CLC Genomics Workbench (version 6.5.2; CLC bio). Variants 
with minor allele frequencies greater than 1% in the dbSNP database 
(version 142) were excluded. Remaining variants were evaluated and 
ranked based on established criteria (3, 4, 52) and pedigree informa-
tion. For families PN-1 and PN-2, whole exome sequencing was per-
formed using the Agilent version 6 enrichment kit and the Illumina 
HiSeq 4000 sequencing system (paired-end reads, 2 × 75 bp) as 
described previously (53). For filtration and prioritization of variants, 
we used the Cologne Center for Genomics’ VARBANK database and 
analysis tool kit (54).
High-throughput mutation analysis by multiplex PCR with subsequent 
next-generation sequencing. As previously described (30, 31), we used 
48.48 Access Array microfluidic technology (Fluidigm) and 2 × 250 bp 
Figure 6. Impact of a NUP37 mutation on the composition of the NPC 
and on nuclear structure. A primary fibroblast cell line from patient PN-2 
with the homozygous truncating mutation p.Arg306* of NUP37 (mutant) 
was compared with control fibroblasts (WT). DAPI stains DNA (blue). (A–C) 
Confocal microscopy of immunostaining for NUP37, NUP107, and NUP160 in 
mutant versus control fibroblasts. (D) Immunoblotting of NUP37, NUP160, 
and NUP107 in mutant versus control fibroblasts. α-Tubulin serves as a 
loading control. Note that protein levels are reduced in mutant fibroblasts. 
(E) Immunostaining with an antibody against several FG-repeat nucleo-
porins (mAb414) in control (left) versus mutant (right) fibroblasts. (F) 
Quantification of E demonstrates a significant reduction in the number 
of NPCs per square micrometer in mutant versus control cells. Data were 
obtained for 100 cells from 3 different experiments. Error bars denote SEM. 
P = 0.0048 (Student’s t test). (G) Immunostaining of HP1β (green), labeling 
heterochromatin, demonstrates an altered pattern in mutant versus control 
fibroblasts. (H) Fibrillarin (green) was used to stain nucleoli. Note that fibril-
larin staining was more dispersed in mutant fibroblasts. (I) Quantification 
of 150 cells from 3 independent experiments demonstrates a significantly 
increased percentage of nuclei with abnormal nucleoli in mutant versus 
control cells. Error bars represent SEM. P = 0.0018 (Student’s t test). Scale 
bars in A–C, E, G, and H: 5 μm. (J–M) TEM images of control versus mutant 
fibroblasts. In control (WT) cells, a regular nuclear envelope (arrow outside 
the nucleus in J) and well-arranged heterochromatin in the proximity of the 
nuclear envelope (arrow inside the nucleus in J) can be seen. Note that the 
nuclear architecture of mutant fibroblasts is altered; specifically, (a) there is 
abnormal arrangement of heterochromatin and nucleoli (arrowheads, J vs. 
K); (b) the perinuclear space is widened and irregular (arrows, L vs. M); and 
(c) bulbous invasions of the nuclear envelope were observed (star, M). Scale 
bars are defined in each image. Immunofluorescence experiments (A–C, E, 
G, and H) and immunoblotting results (D) were confirmed in 3 independent 
experiments. **P < 0.01.
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bly expressing the inducible Cas9-P2A-GFP system with empty vector 
(MOCK) or single gRNA targeting NUP107, NUP85, or NUP133. Fifty 
cells for each condition were analyzed. The GFP signal confirmed 
expression of Cas9-P2A-GFP. Phalloidin stained F-actin fibers and 
was used to identify filopodia. To score cells as “filopodia positive” 
or “filopodia negative,” we used the 2 following criteria: (a) cells that 
displayed at least 1 filamentous protrusion with a length of more than 
one-quarter of the cell diameter, or (b) cells that had 3 or more actin-
based, spike-like protrusions. Cells that fulfilled one or both criteria 
were scored as filopodia-positive cells.
Images in Figure 6 and Supplemental Figure 16A were taken 
with a confocal laser scanning microscope (TCS SP8 gSTED, 
Leica Microsystems) or a confocal microscope (LSM TCS SP5, 
Leica Microsystems). Nuclear pore density was analyzed using the 
“particle analysis” tool of ImageJ (version 1.51z; NIH). Samples were 
prepared for transmission electron microscope as reported previously 
(60) and viewed with a transmission electron microscope (JEOL 
JEM2100PLUS). Quantitative PCR experiments were performed as 
described previously (53). The cell proliferation assay was performed 
as described previously (57). 
Assessment of the cell migration rate of immortalized human podocytes 
with CRISPR/Cas9–mediated knockout of NUP85, NUP107, or NUP133. 
We used the IncuCyte video microscopy system (Essen Biosciences). 
Podocytes were seeded on a 96-well plate and grown to confluence, 
and a standardized scratch wound was made using the Woundmaker 
device according to protocol. Wound closure was recorded by live cell 
imaging every hour for 20–24 hours. Data analysis was performed 
using the IncuCyte 96-well Kinetic Cell Migration and Invasion Assay 
software module. Individual data points are presented as mean ± SD 
resulting from at least triplicate measurements. Experiments were 
repeated 3 times independently.
Generation and characterization of stable zebrafish lines with CRISPR/
Cas9–mediated introduction of hypomorphic or truncating mutations of 
nup107 or nup85. We designed single gRNA targeting exon 2 of nup107 
and exon 4 of nup85 using the CHOPCHOP online tool (https://
chopchop.rc.fas.harvard.edu) (61). Single gRNA and recombinant 
Cas9 protein were injected at the 1-cell stage. Successful mutagenesis 
was determined by a T7 endonuclease assay as described previously 
(62). Positive clutches were raised to adulthood and outcrossed against 
WT fish. Founder lines were genotyped using Sanger sequencing. 
We chose 1 line with a truncating mutation of nup107 (c.50_56del7, 
p.Thr81Argfs*74), 1 line with an in-frame deletion mutation of nup107 
(c.137_139del3, pAla46delAla), and 1 line carrying a null allele of nup85 
(c.323_332delGAGCCTGTATinsGCT, p.Arg107Cysfs*15).
Phenotyping in zebrafish larvae. We generated Kaplan-Meier 
survival curves by comparing WT, heterozygous, and knockout larvae. 
During the experimental period, we monitored the phenotype twice 
daily. All dead larvae and all surviving fish were genotyped at the end 
of the experiment using Sanger sequencing.
Phenotyping was performed at 4 dpf for nup107 fish and 7 dpf for 
nup85 fish. Zebrafish with ventral body axis curvature were imaged 
from a lateral view. Therefore, other parameters were not assessed 
in those fish. Larvae with normal body axis were imaged from a 
dorsal view. To determine eye size, we measured the surface of the 
black pigmented epithelium in the retina using the program ImageJ. 
We defined body edema as the presence of a clear, fluid-filled space 
around the torso in dorsal view, and periorbital edema as the presence 
ated using the T7 mMessage machine kit (Ambion, Thermo Fisher Sci-
entific). Five nanograms of MOs were injected for knockdown experi-
ments, 10 ng of MOs for rescue experiments, and 200 pg of mRNA. 
To label the pronephros, we detected Xenopus atp1a1 expression by 
generating a digoxigenin-labeled antisense probe using the T7 High 
Yield RNA Synthesis kit (New England Biolabs, E2040S). Embryos 
were collected at stage 35–37. Whole mount in situ hybridization was 
done as previously described (59). We qualitatively assessed pro-
nephric morphology based on atp1a1 expression. Abnormalities were 
designated as mild, moderate, or severe (Figure 3B). All experiments 
were performed a minimum of 2 times, and numbers stated in graphs 
are the composite of multiple experiments. Statistical significance of 
glomerular abnormalities and rescues was evaluated by Fisher’s exact 
tests using GraphPad Prism version 7.00 (GraphPad Software). In all 
figures, statistical significance was defined as P < 0.05. P values, as 
indicates by asterisks, are defined in the respective figure legends. See 
Supplemental Methods for a more detailed description.
G-Lisa for active Cdc42. Active Cdc42 was assessed in immortal-
ized human podocytes stably expressing doxycycline-inducible Cas9-
P2A-GFP and single gRNAs targeting NUP107, NUP85, or NUP133 or no 
gRNA (MOCK). The measurements were performed using the colori-
metric G-LISA Cdc42 Activation Assay Kit (Cytoskeleton Inc.) follow-
ing the manufacturer’s instructions. Results are given as absorbance 
value at 490 nm and are normalized to the control condition (MOCK). 
Individual data points in Figure 4 represent the mean of 2 technical 
replicates derived from 3 independent experiments and are displayed 
in different colors with mean and SD. Statistical significance was calcu-
lated using 1-way ANOVA with a standard confidence interval of 95%. F 
values resulting from ANOVA and 2-tailed P values derived from Šidák 
multivariate analysis are indicated. Statistical analysis was performed 
using GraphPad Prism. P < 0.05 was considered statistically significant.
Immunofluorescence, confocal microscopy, and quantification of filo-
podia. Confocal imaging in human podocytes was performed using 
the Leica SP5X system with an upright DM6000 microscope, and 
images were processed with the Leica AF software suite. Experiments 
for filopodia quantification were performed in human podocytes sta-
Table 2. Quantification of phenotypes in homozygous nup107-
knockout zebrafish larvae (p.Thr81Argfs*74)
Small  
eyes
Ventral 
curvatureA
Body  
edemaB
Periorbital 
edemaB,C
Normal
Homozygous 11 18 7 5 0
Heterozygous 0 0 0 0 42
WT 0 0 0 0 34
Definitions of assessed phenotypes: Small eyes: assessed by measurement 
of the surface area of the retinal pigmented epithelium in dorsal view 
images (see yellow drawn circumferences in Figure 5, C and D). Body 
edema: defined as a clear, fluid-filled space around the torso in dorsal view 
images (see Figure 5G). Periorbital edema: defined as a clear, fluid-filled 
space before and/or behind the retinal pigment epithelium of the eyes in 
the dorsal view (see Figure 5G). AEye size and body and periorbital edema 
could not by assessed in ventrally curved fish (see Figure 5F; n = 18). BAll 
fish with either body edema or periorbital edema had small eyes. CFive of 
seven homozygous p.Thr81Argfs*74 fish with small eyes and body edema 
also had periorbital edema.
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